UNSPSC 51372321: Fentanyl citrate

This classification denotes an opioid receptor agonist with the molecular formula C22H28N2O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MUN5LYG46H, chemically known as propionanilide, n-(1-phenethyl-4-piperidyl)- but more generally known as fentanyl citrate, which bears US NIH Compound Identifier 3345. European Medicines Agency schedules Fentanyl citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02129MIG.

Most nations, for tariff and trade purposes, schedule fentanyl citrate under HS 29333300 and SITC 51574. As of Q4 2014, FENTANYL CITRATE remains US FDA's Preferred Term for this commodity. Fentanyl citrate bears US NLM identifiers UMLS ID C0546864 and NCI Concept Code C47994. SMILES: CCC(=O)N(C1CCCCC1)C2CCN(CC2)CCC3CCCCC3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51372321 Fentanyl citrate is a Commodity code that in practice covers a narrow slice of state and local pharmaceutical procurement—primarily opioid-management and emergency-response medications sourced through health departments, county health systems, and multistate cooperative purchasing vehicles. State and local governments use this code to procure controlled pharmaceuticals for public health initiatives, emergency medical services, and community health programs, often bundled with complementary products such as naloxone and drug deactivation systems. The buying base is fragmented across state health and human services departments, county health agencies, and cooperative purchasing consortia serving multiple jurisdictions; no single issuing body dominates recent activity.

Recent opportunities show activity concentrated in Florida and Minnesota-anchored multistate purchasing. Seminole County, Florida released an IFB (No. IFB60459723LAS, response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option on a fixed-fee basis. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (No. S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities including Oregon, requiring vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards; awards were to be made by May 15, 2026. The Texas Health and Human Services Commission posted an RFI (No. HHS0017013, response deadline April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs, representing exploratory procurement before formal solicitation. The code shows limited recent high-visibility activity; most procurement under this code operates through standing cooperative agreements rather than discrete open solicitations.